UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
Iran War Escalates as US, Houthis Target Ships Near Key Oil Routes 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
US Judge Dismisses Gautam Adani Criminal Charges 
ADNOC Gas Targets Up to $4B Profit in 2026 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
KOSPI Rebounds 20% as Samsung, SK Hynix Lead South Korea Stock Rally 
Singapore Raises 2026 GDP Growth Forecast to 4.5%-5.5% as AI Boom Fuels Economy 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
